Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer

Eur Urol. 1989;16(6):426-32.

Abstract

Twelve patients (age range: 53-78 years) with prostatic cancer were treated with Buserelin (1.2 mg/day) and cyproterone acetate (150 mg/day). Testicular biopsies performed after 13-96 weeks of treatment were compared to those obtained from 6 untreated men of similar age. Deranged spermatogenesis was observed in all but 1 treated patient. The appearance of immature Sertoli cells and atrophic Leydig cells suggests a condition of pharmacologic 'hypophysectomy'. The variable damage to the seminiferous epithelium and findings of an incomplete involution of Leydig cells suggested a decreased but still present testicular steroidogenesis.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Buserelin / administration & dosage
  • Cyproterone / administration & dosage
  • Cyproterone / analogs & derivatives
  • Cyproterone Acetate
  • Drug Therapy, Combination
  • Humans
  • Leydig Cells / drug effects
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Sertoli Cells / drug effects
  • Spermatogenesis / drug effects
  • Testicular Diseases / chemically induced*
  • Testicular Diseases / pathology
  • Testosterone / blood

Substances

  • Testosterone
  • Cyproterone Acetate
  • Cyproterone
  • Buserelin